title: Vasorelaxant properties of norbormide, a selective vasoconstrictor agent for the rat microvasculature.
abstract: 1. The effects of norbormide on the contractility of endothelium-deprived rat, guinea-pig, mouse, and human artery rings, and of freshly isolated smooth muscle cells of rat caudal artery were investigated. In addition, the effect of norbormide on intracellular calcium levels of A7r5 cells was evaluated. 2. In resting rat mesenteric, renal, and caudal arteries, norbormide (0.5-50 microM) induced a concentration-dependent contractile effect. In rat caudal artery, the contraction was very slowly reversible on washing, completely abolished in the absence of extracellular calcium, and antagonized by high concentrations (10-800 microM) of verapamil. The norbormide effect persisted upon removal of either extracellular Na+ or K+. The contractile effect of norbormide was observed also in single, freshly isolated smooth muscle cells from rat caudal artery. 3. In resting rat and guinea-pig aortae, guinea-pig mesenteric artery, mouse caudal artery, and human subcutaneous resistance arteries, norbormide did not induce contraction. When these vessels were contracted by 80 mM KCl, norbormide (10-100 microM) caused relaxation. Norbormide inhibited the response to Ca2+ of rat aorta incubated in 80 mM KCl/Ca2(+)-free medium. Norbormide (up to 100 microM) was ineffective in phenylephrine-contracted guinea-pig and rat aorta. 4. In A7r5 cells, a cell line from rat aorta, norbormide prevented high K(+)- but not 5-hydroxytryptamine-induced intracellular calcium transients. 5. These findings indicate that in vitro, norbormide induces a myogenic contraction, selective for the rat small vessels, by promoting calcium entry in smooth muscle cells, presumably through calcium channels. In rat aorta and arteries from other mammals, norbormide behaves like a calcium channel entry blocker.
authors.affiliation: Department of Pharmacology, University of Padova, Italy.
authors.forename: S
authors.initials: S
authors.lastname: Bova
authors.forename: L
authors.initials: L
authors.lastname: Trevisi
authors.forename: P
authors.initials: P
authors.lastname: Debetto
authors.forename: L
authors.initials: L
authors.lastname: Cima
authors.forename: M
authors.initials: M
authors.lastname: Furnari
authors.forename: S
authors.initials: S
authors.lastname: Luciani
authors.forename: R
authors.initials: R
authors.lastname: Padrini
authors.forename: G
authors.initials: G
authors.lastname: Cargnelli
mesh_terms: D000818:Animals; D002118:Calcium / Q000378:metabolism; D002460:Cell Line; D004305:Dose-Response Relationship, Drug; D006168:Guinea Pigs; D006801:Humans; D008297:Male; D051379:Mice; D008833:Microcirculation / Q000187:drug effects*; D009131:Muscle, Smooth, Vascular / Q000187:drug effects*; D009636:Norbornanes / Q000494:pharmacology*; D051381:Rats; D017207:Rats, Sprague-Dawley; D014662:Vasoconstrictor Agents / Q000494:pharmacology*; D014664:Vasodilation
chemical_list: D009636:Norbornanes; D014662:Vasoconstrictor Agents; C005321:norbormide; D002118:Calcium